Replies to post #1780 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

>This would answer part of the reason for the market overlooking the current cash levels as it pertains to the PPS.<

I agree; however, as stated in #msg-22707854, the valuation is dirt cheap even after accounting for the cash burn during the rest of the year.

>When does IDIX plan to at least break-even on Tyzeka.<

They haven’t answered this explicitly, but they’ve given guidance of $20M in worldwide Tyzeka sales for 2007.

If you expect, as I do, that Tyzeka’s sales ramp will be similar to Baraclude’s (#msg-21567340), Tyzeka-related operating losses should drop abruptly in a couple of quarters and a Tyzeka operating profit ought to be attainable by early 2009.